-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Barclays Boosts Legend Biotech (NASDAQ:LEGN) Price Target to $65.00
Barclays Boosts Legend Biotech (NASDAQ:LEGN) Price Target to $65.00
Legend Biotech (NASDAQ:LEGN – Get Rating) had its target price raised by Barclays from $53.00 to $65.00 in a report released on Wednesday, The Fly reports. They currently have an overweight rating on the stock.
Several other equities analysts have also commented on LEGN. Piper Sandler upped their target price on Legend Biotech from $72.00 to $78.00 and gave the company an overweight rating in a report on Tuesday, December 20th. Morgan Stanley upped their target price on Legend Biotech from $60.00 to $65.00 and gave the company an overweight rating in a report on Tuesday. Evercore ISI started coverage on Legend Biotech in a report on Tuesday, November 1st. They set an outperform rating for the company. UBS Group started coverage on Legend Biotech in a report on Tuesday, December 6th. They set a buy rating and a $66.00 target price for the company. Finally, Cowen started coverage on Legend Biotech in a report on Tuesday, November 1st. They issued an outperform rating for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $70.14.
Get Legend Biotech alerts:Legend Biotech Stock Down 2.1 %
Shares of Legend Biotech stock opened at $52.71 on Wednesday. The firm has a market cap of $8.65 billion, a P/E ratio of -45.24 and a beta of -0.13. The business has a 50-day moving average price of $51.28 and a 200 day moving average price of $48.02. Legend Biotech has a fifty-two week low of $30.75 and a fifty-two week high of $57.72.
Hedge Funds Weigh In On Legend Biotech
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new stake in Legend Biotech in the second quarter worth approximately $33,000. Macquarie Group Ltd. lifted its position in Legend Biotech by 78.5% in the third quarter. Macquarie Group Ltd. now owns 2,951 shares of the company's stock worth $121,000 after purchasing an additional 1,298 shares during the period. Nomura Holdings Inc. acquired a new stake in Legend Biotech in the second quarter worth approximately $215,000. Dupont Capital Management Corp acquired a new stake in Legend Biotech in the fourth quarter worth approximately $216,000. Finally, Ensign Peak Advisors Inc lifted its position in Legend Biotech by 157.1% in the third quarter. Ensign Peak Advisors Inc now owns 5,400 shares of the company's stock worth $220,000 after purchasing an additional 3,300 shares during the period. 38.88% of the stock is owned by institutional investors.Legend Biotech Company Profile
(Get Rating)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
Read More
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
传奇生物(纳斯达克:乐高-获得评级)据The Fly报道,巴克莱在周三发布的一份报告中将其目标价从53.00美元上调至65.00美元。他们目前对该股的评级为增持。
其他几位股票分析师也对LEGN发表了评论。派珀·桑德勒在12月20日(周二)的一份报告中将该公司在传奇生物上的目标价从72美元上调至78美元,并给予该公司加码评级。摩根士丹利在周二的一份报告中将其在传奇生物的目标价从60.00美元上调至65.00美元,并给予该公司加码评级。Evercore ISI在11月1日星期二的一份报告中开始在传奇生物上报道。他们为该公司设定了表现优于大盘的评级。瑞银集团在12月6日星期二的一份报告中开始在传奇生物上进行报道。他们为该公司设定了买入评级和66.00美元的目标价。最后,考恩在11月1日星期二的一篇报道中开始在传奇生物上进行报道。他们为该公司发布了表现优于大盘的评级。一名股票研究分析师对该股的评级为持有,九名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股目前的共识评级为适度买入,共识目标价为70.14美元。
到达传奇生物警报:传奇生物股价下跌2.1%
周三,传奇生物的股价开盘报52.71美元。该公司的市值为86.5亿美元,市盈率为-45.24,贝塔系数为-0.13。该业务的50日移动均线价格为51.28美元,200日移动均线价格为48.02美元。传奇生物目前跌至52周低点30.75美元和52周高点57.72美元。
对冲基金在传奇生物上发表看法
机构投资者和对冲基金最近增持或减持了该业务的股份。今年第二季度,美国国际集团收购了传奇生物价值约33,000美元的新股份。麦格理集团(Macquarie Group Ltd.)在第三季度将其在传奇生物的持仓提高了78.5%。麦格理集团(Macquarie Group Ltd.)在此期间又购买了1,298股,目前持有该公司2,951股股票,价值12.1万美元。野村控股有限公司(Nomura Holdings Inc.)在第二季度新购入传奇生物股份,价值约215,000美元。杜邦资本管理公司(DuPont Capital Management Corp)在第四季度收购了传奇生物价值约216,000美元的新股份。最后,Ensign Peak Advisors Inc.在第三季度将其在传奇生物的持仓提高了157.1%。Ensign Peak Advisors Inc.在此期间额外购买了3,300股票,现在拥有5,400股该公司股票,价值220,000美元。38.88%的股份由机构投资者持有。传奇生物公司简介
(获取评级)
传奇生物是一家临床阶段的生物制药公司,通过其子公司,在美国和国际上从事肿瘤和其他适应症的新型细胞疗法的发现和开发,中国说。其主要候选产品LCAR-B38M是一种用于治疗多发性骨髓瘤(MM)的嵌合抗原受体,并与标准三联疗法治疗难治性多发性骨髓瘤进行了比较。
阅读更多内容
- 在传奇生物上免费获取斯托克新闻网的研究报告(乐高)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
接受传奇生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对传奇生物及相关公司评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧